Funding Priorities

Review Multidisciplinary Association for Psychedelic Studies on Great Nonprofits
Review Multidisciplinary Association for Psychedelic Studies on Great Nonprofits

Since our founding in 1986, MAPS has disbursed over $46 million to developing psychedelics and marijuana into prescription medicines for some of the most hard-to-treat illnesses and to educating the public honestly about the risks and benefits of these substances.

Every dollar has come from private donors committed to our mission. The pharmaceutical industry and federal government have not yet supported our work, so the continued expansion of psychedelic research still relies on the generosity of individual donors and foundations.

Our additional research projects include our observational studies of ayahuasca treatment for PTSD and ibogaine treatment for opiate addiction. Our randomized, controlled, double-blind study of smoked marijuana for PTSD in 76 veterans has approval from the U.S. Food and Drug Administration (FDA), U.S Drug Enforcement Administration (DEA), and Institutional Review Boards (IRBs) at the University of Pennsylvania, Johns Hopkins University, and the Copernicus IRB. The U.S. Department of Health and Human Services (HHS) has agreed that the National Institute on Drug Abuse (NIDA) will provide the marijuana for the study. We anticipate starting the study in the summer of 2016. This study is funded by a $2.15 million grant to MAPS from the Colorado Department of Public Health and Environment, our first government grant in the history of MAPS.

Donations can be restricted to specific projects or allocated to our general fund. Most of our funding needs are for research, but we also rely on your contributions for our educational mission and to maintain daily operations. MAPS sponsors research in both non-institutional and institutional settings; our Board of Directors has established a policy of limiting indirect overhead expenses for research in institutional settings to 10%.

We are also seeking bequests, in addition to gifts of cash, stock, real estate, art, and other goods (the four largest donations in MAPS’ history have all been bequests). Learn about including MAPS in your will or trust.

Donations to MAPS are tax-deductible for individuals residing in the United States. Tax deductions are also available through ally organizations for contributors in the United Kingdom (through the Beckley Foundation), Switzerland (through SaePT), Canada (through MAPS Canada), and Israel (through Beer Yaakov Hospital). If you live outside the U.S. and would like your gift to be tax-deductible, please contact our office at orders@maps.org or at (831) 429-MDMA (6362).

MDMA-Assisted Therapy for PTSD Research Fund

Developing MDMA (3,4-methylenedioxymethamphetamine) into an FDA-approved prescription medicine for PTSD is our top funding priority. We have successfully conducted Phase 2 clinical trials of MDMA-assisted psychotherapy in the United States, Canada, Israel, and Switzerland. Phase 3 clinical trials will begin in 2018 in the U.S., Canada, and Israel with an initial study of 100-150 participants.

To learn more about why MDMA-assisted psychotherapy holds such promise for PTSD patients, download one of our brochures or visit mdmaptsd.org.

We are transitioning into Phase 3 of our drug development program. The FDA has approved our study protocol and has granted MDMA-assisted psychotherapy a Breakthrough Therapy designation. What are Phase 2 and Phase 3 trials?

Our results from our Phase 2 studies have been promising: after 12 months of follow-up, 67% of patients who received MDMA-assisted psychotherapy no longer met the criteria for PTSD. Phase 2 research began in 2001 and recently concluded with 107 treatment-resistant PTSD patients from the U.S., Switzerland, Israel, and Canada. In a small subset of these patients who were followed an average of 3.8 years after treatment, outcomes were sustained indicating that durable remission is possible over even longer periods significant and lasting improvements (published in July 2010 in the Journal of Psychopharmacology). A long-term follow-up of patients who received MDMA-assisted psychotherapy revealed that overall benefits were maintained an average of 3.8 years later (published January 2013 in the Journal of Psychopharmacology.

Please donate today to help make MDMA-assisted psychotherapy a legal treatment.

See MAPS in the Media for regular news coverage of our MDMA-assisted psychotherapy research program.

Training Protocol for MDMA-Assisted Therapy (South Carolina)
$429,000 needed • $160,000 raised • $269,000 still needed

MDMA-Assisted Therapy for PTSD (Cognitive Behavioral Conjoint Therapy)
$235,000 study cost • $165,000 raised • $70,000 still needed